Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer Article

Belani, Chandra P., Nemunaitis, John J., Chachoua, Abraham et al. (2013). Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer . CANCER BIOLOGY & THERAPY, 14(7), 557-563. 10.4161/cbt.24598



Industry Collaboration

cited authors

  • Belani, Chandra P.; Nemunaitis, John J.; Chachoua, Abraham; Eisenberg, Peter D.; Raez, Luiz E.; Cuevas, J. Daniel; Mather, Cecile B.; Benner, Rebecca J.; Meech, Sandra J.

fiu authors

publication date

  • 2013

webpage

published in

Digital Object Identifier (DOI)

start page

  • 557

end page

  • 563

volume

  • 14

issue

  • 7

research area

  • Oncology  Web of Science Research Area